Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on innovative treatments for pattern hair loss. Its lead program, VDPHL01, is a proprietary extended-release oral minoxidil tablet studied for mild-to-moderate androgenetic alopecia. The company aims to build a focused portfolio of aesthetic dermatology candidates for common, under-served skin and hair conditions. As a clinical-stage firm with negligible product sales, value hinges on pipeline progress rather than commercial operations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -6.5 | — |
| Q1 2025 | 0 | — | -14.6 | — |
| Q4 2025 | 0 | — | -28.2 | — |
| Q1 2026 | 0 | — | -30 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Skeena Resources Limited (SKE), Valvoline Inc. (VVV), Q2 Holdings, Inc. (QTWO), Lemonade, Inc. (LMND), Avient Corporation (AVNT), Bread Financial Holdings, Inc. (BFH)